Introduction
============

Giant cell arteritis (GCA) is a vasculitis involving large- and medium-size vessels, especially the cranial branches derived from the carotid artery.[@b1-clep-10-1533] GCA is relatively common in adults aged over 50 years with an incidence of 1/10,000 person-years and may lead to severe ischemic complications like visual loss, aortic aneurism, or stroke.[@b1-clep-10-1533],[@b2-clep-10-1533] Polymyalgia rheumatica (PMR) is present in up to 50% of patients with GCA and may begin before, simultaneously, or after the clinical manifestations of GCA, suggesting they are different spectrums of the same disease process.[@b3-clep-10-1533]

The pathophysiology of GCA is not fully understood, but the role of cellular actors has been investigated in recent years. Schematically, an unknown antigen present in the vascular wall appears to activate dendritic cells in the adventitia. Consequently, recruitment and activation of CD4 T cells and then the macrophages lead to vascular inflammation and remodeling. As for other vasculitis, it is suspected that an antigen of infectious origin may trigger GCA by interacting with an appropriate genetic condition in an individual.[@b4-clep-10-1533]

It has been suggested that a hyper-effective immune system or "hyper-immunity" is central to the pathogenesis of GCA/PMR.[@b5-clep-10-1533],[@b6-clep-10-1533] This concept, recent and not yet well defined, refers to a state of over-activation of the innate immune system. Dendritic cells are highly efficient in sensing bacterial products and facilitating T-cell recruitment.[@b5-clep-10-1533] A hyper-effective immune system might thus protect against infections in general and, on the other hand, lead to increased risk of GCA/PMR.

Several previous studies have examined infection risks following a diagnosis of GCA/PMR. Most of them reported an increased subsequent risk of incident infections or mortality due to infectious diseases.[@b7-clep-10-1533]--[@b12-clep-10-1533] For example, Schmidt et al found that severe infections were more common in GCA patients compared to subjects without GCA during the first year of follow-up (incidence rate ratio=2.1; 95% CI: 1.2--3.4).[@b11-clep-10-1533] However, such increased infection risk may be related to corticosteroid treatment and other acute therapy, increased surveillance and healthcare contacts, and other comorbid conditions.[@b12-clep-10-1533] One recent matched case--control study from the UK examined the association between previous infections and incident GCA. This study found a modest positive association, thus not supporting the hypothesis of hyper-immunity.[@b13-clep-10-1533]

To examine if a decreased risk of infection, as a marker of hyper-immunity, can predict an increased subsequent risk of GCA/PMR in the Danish population, we conducted a large population-based case--control study.

Patients and methods
====================

Study setting
-------------

The source population was all inhabitants of the Central and the North Denmark Region (\~1.8 million individuals).[@b14-clep-10-1533]

Data sources
------------

We used three databases: the Danish National Patient Registry (DNPR), the Danish Pathology Registry (DPR), and the Aarhus University Prescription Database (AUPD). All Danish population has free and unrestricted access to medical care and is assigned a unique identification number (the Central Personal Registry number) upon birth or immigration, which allows unambiguous electronic linkage across the data sources.[@b15-clep-10-1533] The DNPR uses the International Classification of Diseases (ICD) system (ICD-8th revision until 1994 and ICD-10th revision thereafter) to collect information on dates and diagnoses of all hospitalizations in Denmark since 1977 and on all outpatient visits since 1995.[@b16-clep-10-1533]The DPR includes information on all pathology specimens from any pathology department in Denmark since 1997.[@b17-clep-10-1533]The AUPD contains data on all prescription drugs redeemed by Danish citizens at monopolized community pharmacies in Central and North Denmark Regions with complete data since 1996. Drugs are categorized according to the anatomical therapeutic chemical (ATC) code. Prescription data include the date of dispensing, the substance, brand name, and quantity. The dosing instruction and the indication for prescribing are not recorded.[@b14-clep-10-1533]

Identification of cases with CGA/PMR
------------------------------------

From the DNPR, we included all patients with an incident event of GCA and/or PMR (ICD-10 codes: M31.5 or 31.6 and 35.3, respectively) diagnosed for the first time between January 1, 1997, and December 31, 2012. For each patient, information on gender, date of birth, and date of GCA/PMR diagnosis (the index date) was collected. For each case, the index date was defined as the date of the diagnosis of GCA/PMR, whereas for each control (see below), the index date was the time at which GCA/PMR occurred for the matched case. Because GCA and PMR may be different diseases, or different progressive aspects of the same disease, we categorized cases into three subgroups according to the diagnosis: PMR subgroup including all patients with a diagnosis of PMR without associated GCA at diagnosis or during the follow-up.GCA subgroup including all patients with a diagnosis of GCA without associated PMR at diagnosis or during the follow-up.GCA+PMR subgroup including all patients with a diagnosis of both GCA and PMR.

A definitive diagnosis of GCA is based on a temporal artery biopsy with documented inflammatory lesions in the artery wall. Thus, for GCA or GCA+PMR subgroups, we identified all patients who had a GCA with a positive temporal artery biopsy (TAB) (Snomed code M40160 and T45270) or a negative TAB using the DPR.

Exclusion criteria for cases were: age \<50 years at the time of diagnosis of GCA/PMR, diagnosis of GCA/PMR outside the Central and the North Denmark Region, and patients who had \<1 year of residence in this region before their GCA/PMR diagnosis in order to collect enough exposure and covariate data.

Identification of population controls
-------------------------------------

We used the Danish Civil Registration System to identify 10 population controls for each case. Controls had to be residents of the Central or North Denmark Region, and the same exclusion criteria as for GCA/PMR cases applied. We matched these controls on gender, year of birth, region of residence, and time spent in the region (in years) before the index date.

Assessment of exposure to infection
-----------------------------------

The study exposure was either hospital-treated infection or community-based anti-infective prescription occurring before the index date. We used DNPR to identify any first-time inpatient admission or hospital outpatient contact for the treatment of an infectious disease in both case and control groups. We examined a range of infections according to the system or organ involved and by the type of pathogen (see [Tables S1](#SD1-clep-10-1533){ref-type="supplementary-material"}--[S3](#SD3-clep-10-1533){ref-type="supplementary-material"} for ICD codes). We used the AUPD to collect redemption of anti-infective prescriptions as evidence of community anti-infective treatment. We examined different subgroups of anti-infectives commonly prescribed to treat specific infections (see [Table S4](#SD4-clep-10-1533){ref-type="supplementary-material"} for ATC codes).

Covariates
----------

To control for confounding, we ascertained data on other factors potentially associated with GCA/PMR that may also be associated with infection risks from the DNPR and the AUPD. For each case and control subject, we collected data on diabetes, chronic alcoholism-related conditions, disorders involving immune mechanisms (such as common variable immunodeficiency or Wiskott--Aldrich syndrome), any exposure of immunosuppressive treatment including corticosteroid use, chronic kidney insufficiency, malnutrition, and history of malignant neoplasm (see [Table S5](#SD5-clep-10-1533){ref-type="supplementary-material"} for ICD and ATC codes used).

Statistical analyses
--------------------

Descriptive statistics were used to summarize the characteristics of GCA/PMR cases and controls. We used conditional logistic regression to compute crude and adjusted ORs with associated 95% CI for GCA/PMR, among persons with and without hospital- or community-treated infections occurring at least 1 year before the index date. In secondary analyses, we separately examined infections occurring during the last 12 months preceding the index date. This distinction was made because infections shortly before GCA/PMR diagnosis may either indicate reverse causality (ie, early incubating GCA/PMR with malaise, healthcare contacts, or treatment attempts leading to infections) misclassification (early GCA/PMR symptoms such as fever being misdiagnosed as infection) or, alternatively, indicate a short-term triggering effect of infections in the pathogenesis of GCA/PMR. In contrast, infection risk \>12 months before GCA/PMR diagnosis may be more reflective of the overall longer-term immune status in individuals. For each exposure period, we performed analyses among case and control pair subsets according to subgroups of GCA/PMR disease: PMR only, GCA only, GCA+PMR, and GCA with positive or negative TAB. In all models, we adjusted for diabetes, chronic alcoholism-related conditions, disorders involving the immune system, any exposure of immunosuppressive treatment, chronic kidney insufficiency, malnutrition, and malignancies. All analyses were conducted using SAS software.

Ethics approval
===============

The Danish Data Protection Agency approved the study. According to Danish law, this registry-based study needed no further ethical approval.

Results
=======

Characteristics of study population
-----------------------------------

We identified 8,859 incident cases of GCA/PMR in the Central and the North Denmark Regions between 1997 and 2012. We excluded 234 patients who were aged \<50 years, 1,167 who did not live in the region on the date of their diagnosis, and 233 who lived \<1 year in the region before their diagnosis.

Finally, we included 7,225 cases and 72,250 controls. Median age at the time of diagnosis was 74 years (interquartile range \[IQR\] 67--81), and 64% were females ([Table 1](#t1-clep-10-1533){ref-type="table"}). Potential confounding factors were equally distributed between GCA/PMR patients and controls, except for diabetes, chronic kidney disease, and use of oral corticosteroids, which were more common in GCA/PMR cases.

Infections occurring at least 1 year prior to the index date and risk of GCA/PMR
--------------------------------------------------------------------------------

After exclusion of infections occurring 12 months preceding the index date, 2,426 (33.6%) cases and 20,806 (28.8%) controls had a history of hospital-treated infectious diseases. The most common diagnoses in both groups were digestive system infections (11.4%) followed by infections of the respiratory tract (9.7%) and the urinary tract (7.7%). Compared to those without infection, patients with history of hospital-treated infection had a higher risk of developing GCA/PMR (OR=1.26, 95% CI: 1.19--1.32). After controlling for various confounders, the adjusted OR for the association between hospital-treated infection was close to 1 (adjusted OR=1.04, 95% CI: 0.98--1.10). Main confounding factors were oral corticosteroid use, diabetes, and chronic kidney disease. When we focused on infections according to systems or organs involved, no subgroup of infection was associated with a materially decreased or increased risk of GCA/PMR ([Table 2](#t2-clep-10-1533){ref-type="table"}).

In total, 6,147 (85.1%) GCA/PMR patients and 58,677 (81.2%) controls had redeemed anti-infective treatment prescriptions \>12 months before the index date. The most common anti-infective treatments prescribed were antibiotics typically used for respiratory tract infections (67.4%), urinary tract infections (29.7%), and soft tissue or skin infections (11.7%) in both groups. Patients with prescription history of an anti-infective treatment had a higher risk of developing a GCA/PMR (OR=1.41, 95% CI: 1.31--1.52) compared to those without it. After controlling for various confounders, this association reduced considerably (adjusted OR=1.07, 95% CI: 0.99--1.16). No subgroups of anti-infective prescriptions were clearly associated with an altered risk of GCA/PMR, except for treatments typically prescribed for herpes simplex virus (HSV) or varicella-zoster virus (VZV) infection (adjusted OR=1.20, 95% CI: 1.07--1.35) ([Table 2](#t2-clep-10-1533){ref-type="table"}).

Infections occurring 1 year prior to the index date and risk of GCA/PMR
-----------------------------------------------------------------------

During 12 months preceding the index date, 582 (8.1%) cases and 3,074 (4.3%) controls had a history of hospital-treated infection. After adjustment, patients with a history of hospitalization for an infectious disease had an increased risk of developing GCA/PMR (adjusted OR=1.59, 95% CI: 1.44--1.75). An approximately doubled risk was seen for all major infection types, including respiratory tract infections, skin and musculoskeletal infections, or urinary tract and genital infections ([Table 3](#t3-clep-10-1533){ref-type="table"}).

Identically, 3,367 (46.6%) GCA/PMR patients and 23,561 (32.6%) controls redeemed an anti-infective treatment prescription within 12 months before the index date. After adjustment, patients with anti-infective prescription had a clearly increased risk of developing GCA/PMR (adjusted OR =1.63, 95% CI: 1.48--1.79), mainly driven by anti-infective treatment used for respiratory tract infection (adjusted OR=1.53, 95% CI: 1.45--1.62) ([Table 3](#t3-clep-10-1533){ref-type="table"}).

Hospital-treated infections, anti-infective treatments, and risk of different subgroups of GCA/PMR
--------------------------------------------------------------------------------------------------

Among our cases, 5,100 (70.6%) patients had a PMR diagnosis only, 100 (1.4%) had GCA only, and 2,025 (28%) had both GCA and PMR. After exclusion of events occurring in the year prior to the index date, there was an association between hospital-treated infections and the subgroups having a later GCA diagnosis alone or together with PMR (adjusted OR=1.15, 95% CI: 1.04--1.27 and 1.15, CI 95%: 1.04--1.27, respectively) ([Table 4](#t4-clep-10-1533){ref-type="table"}).

Among GCA or GCA+PMR patients, 510 (24%) had a positive TAB and 1,615 (76%) had a negative TAB. Of note, there was no association with hospital-treated infection or prescription of anti-infective treatment for the TAB positive GCA subgroup ([Table 5](#t5-clep-10-1533){ref-type="table"}).

When we focused on infections occurring 12 months before GCA/PMR, OR remained higher for GCA diagnosis alone or together with PMR compared with PMR without GCA ([Table 4](#t4-clep-10-1533){ref-type="table"}).

Discussion
==========

This large population-based study provides evidence that patients with history of infection have a slightly increased, rather than decreased, risk of developing GCA/PMR, arguing against the hypothesis of "hyper-immunity."

Different biological mechanisms might explain the link between increased infections and development of GCA/PMR. Preexisting immune system alterations due to genetic polymorphisms or immunosenescence could increase both infection risk and development of vasculitis in the arterial wall.[@b13-clep-10-1533] Indeed, many genetic polymorphisms involving genes of the immune system are described in GCA/PMR.[@b18-clep-10-1533] For example, haplotypes of human leukocytes antigen (like HLA DRB1\*04), mutations concerning intracellular signalization molecules (like PTPN22 playing a role in T-cell activation), or mutation of genes encoding proinflammatory cytokines (like tumor necrosis factor-α or interleukin-6) are frequently detected in GCA patients.[@b18-clep-10-1533]--[@b20-clep-10-1533] All these polymorphisms could lead to a better cooperation between dendritic cells and T cells, inducing aberrant immune cell activation and the development of an unregulated inflammatory response.[@b5-clep-10-1533] Alternatively, infections could also be directly responsible for GCA/PMR in case of an unregulated inflammatory response. Thus, molecular mimicry, epitope spreading, bystander activation, or exposition of cryptic antigens may all be involved in auto-immunity.[@b21-clep-10-1533] Immunosenescence describes adaptive and innate immune deregulation in the elderly, including contraction of the immune repertoire, impairment of dendritic cells, and excessive secretion of pro-inflammatory cytokines. This results in a pro-inflammatory environment promoting vasculitis and a decreased bacterial clearance.[@b22-clep-10-1533],[@b23-clep-10-1533]

Only two previous studies, to our knowledge, have evaluated the risk of infections before GCA diagnosis. Russo et al included 100 biopsy-proven GCA and 100 gender- and age-matched controls.[@b24-clep-10-1533] The objective of the study was to assess any association between the occurrence of GCA and infections (classified into three groups: possible, probable, and proven infection) 4 months prior to the diagnosis of GCA. Most frequently occurring infections were urinary tract infections, sinusitis, pharyngitis, upper respiratory tract infections, and supposed viral infections. In agreement with our results, the authors demonstrated that recent infections were significantly more common in GCA patients compared to controls, with a relative risk of 3.5 (95% CI: 1.8--7.0). In another recent study, Rhee et al compared 4,559 GCA cases with 22,795 age-, sex-, and practice-matched controls.[@b13-clep-10-1533] Prior infections (classified as respiratory tract, urinary tract, gastrointestinal tract, conjunctiva, or skin and soft tissue infections) were associated with a higher risk of developing GCA with an incidence rate ratio of 1.26 (95% CI: 1.16--1.36). This association persisted for all time periods but was strongest within 6 months prior to the index date, corroborating our findings.

Previous studies have searched for specific microbial agents as infectious triggers of GCA/PMR.[@b25-clep-10-1533]--[@b31-clep-10-1533] The herpes virus group, especially, has been the object of intensive research.[@b32-clep-10-1533] Powers et al analyzed the prevalence of HSV detected by PCR in the temporal arteries of patients with and without biopsy-proven GCA. HSV was more often found in temporal arteries of biopsy-proven GCA patients (21/24, *P*=0.027).[@b33-clep-10-1533] In our study, we found no association between VZV infection and risk of GCA/PMR. Likewise, there was only a modest relation between the use of acyclovir (antiviral treatment used for HSV or VZV) and risk of GCA/PMR with an adjusted OR of 1.20 (95% CI: 1.07--1.35). In comparison, Rhee et al found that herpes zoster infection was associated with a modestly increased risk of GCA (incidence rate ratio=1.17, 95% CI: 1.04--1.31).[@b13-clep-10-1533] On the other hand, we did not find an association between hospitalization for any virus infection and the occurrence of GCA/PMR. When we focused on GCA patients with positive TAB, we did not find any association with neither hospital-treated infections nor prescription of anti-infectives, including anti-viral treatment for HSV or VZV.

It remains to be elucidated to which degree ours and other findings for recent infections are causal or point toward misclassification, that is, beginning symptoms of vasculitis misdiagnosed as infection, or protopathic bias, that is, vasculitis and its treatment causing infection. Of note, we noticed a large difference in corticosteroid prescription (without restriction concerning the dose or the duration of treatments) in GCA/PMR patients compared to controls (58% vs 25%). This difference was particularly evident during the year preceding the index date (45% vs 7%) and likely explained by corticosteroids used to treat the first symptoms of vasculitis before the final diagnosis was made, because in some case, the treatment must be rapidly initiated.[@b34-clep-10-1533] The prescription of corticosteroid showed to be the most important confounder in our study, explaining much of the apparent association between infections and GCA/PMR.

The main strengths of our study are a large number of GCA patients, a population-based design, long and complete follow-up, and the ability to adjust for numerous confounding factors. Concerning limitations, we might risk some misclassification bias due to the registry-based nature of our study. Many infections would not be captured by Danish registries because they are treated with neither hospitalization nor anti-infective treatment. In particular, many viral infections that are suspected to act as trigger in the development of GCA/PMR are associated with no or few symptoms. Moreover, as in any observational study, unmeasured confounders may have affected our risk estimates, such as anthropometric, lifestyle, and genetic factors potentially associated with both infections and risk of GCA/PMR.

We did not collect data about vaccinations. Vaccine components, like adjuvants, can activate the immune system and induce manifestations grouped under the ASIA syndrome (auto-immune/inflammatory syndrome induced by adjuvants). There are case reports of subjects who developed GCA/PMR following influenza vaccination.[@b35-clep-10-1533],[@b36-clep-10-1533] Vaccination, by decreasing infection risk and increasing the development of GCA/PMR could thus be a potential unmeasured con-founder in our study.

Conclusion
==========

Our results do not support the hypothesis of "hyper-immunity" leading to GCA/PMR. Instead, incident GCA/PMR is preceded by a slightly increased risk of infection. This finding may support theories that infections may be directly involved in the pathogenesis of GCA/PMR. However, the finding that the association is strongest for infections close to the GCA diagnosis date, and the strong role of corticosteroid treatment as a confounder, points toward presence of considerable protopathic bias.

Supplementary materials
=======================

###### 

List of all collected infections in the study (ICD-10 codes and equivalent ICD-8 codes)

  ICD-10 code                                                                                                                                                                                                ICD-8 code
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  A00B99                                                                                                                                                                                                     000--018, 020--037, 039--065, 067--134
  D73.3, E06.0, E06.9, E32.1                                                                                                                                                                                 
  G00--G02, G04--G07                                                                                                                                                                                         320, 322--323
  H00, H01.0, H03.0--H03.1, H04.0, H04.3, H05.0, H06.1, H10, H13.1, H19.1--19.2, H22.0, H32.0, H44.0, H60.0--H60.3, H62.0--H62.4, H65.0, H66, H67, H68.0, H70, H73.0, H75.0, H94.0                           361--362, 364, 366.00, 367.00, 368.00, 368.05, 369.00--369.01, 380--384
  I00--I02, I30.1, I32.0--I32.1, I33.0, I38, I39.8, I40.0, I41.0--I41.2, I43.0, I52.0--I52.1, I68.1, I98.1                                                                                                   390--391, 420--424
  J00--J06, J09--J18, J20--J22, J34.0, J36, J39.0--J39.1, J44.0, J85--J86                                                                                                                                    034, 460--466, 470--474, 480--486, 501, 503, 508.00--508.3, 508.5, 510, 513
  K04.0, K04.6--K04.7, K05.2, K11.2--K11.3, K12.2, K23.0--K23.1, K35, K37, K57.0, K57.2, K57.4, K57.8, K61, K63.0, K65.0, K67, K75.0--K75.1, K77.0, K80.0, K80.3--K80.4, K81.0, K83.0, K85.9, K93.0--K93.1   522.59, 527.39, 528.39, 530--542, 567, 569, 572, 575, 577.03
  L00--L03, L05--L08                                                                                                                                                                                         566.00, 680--686
  M00--M03, M46.3, M46.5, M49.0--M49.3, M60.0, M63.0--M63.2, M65.0--M65.1, M71.0--M71.1, M68.0, M86.0--M864, M86.8--M86.9, M90.0--M90.2                                                                      710--711, 720, 732.99
  N10--N12, N13.6, N15.1, N16.0, N29.1, N30.0, N33.0, N34.0--N34.1, N39.0, N41, N43.1, N45, N48.1--N48.2, N49, N51, N61, N70-77                                                                              590, 595, 599.00, 599.06, 597.03, 601, 604, 612--614, 616, 620, 622, 626.49
  R57.2, R65.0--R65.1, R75                                                                                                                                                                                   038
  T80.2, T81.4, T82.6--T82.7, T83.5--T83.6, T84.5--T84.7, T85.7, T88.0                                                                                                                                       997.69, 998.59, 998.79, 999.39

###### 

Infectious diseases according to systems or organs involved (ICD-10 codes and equivalent ICD-8 codes)

  System or organ                                                                                                                 ICD-10 code                                                                                                                                                                                                                    ICD-8 code
  ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------
  Infections of the nervous system                                                                                                A80--A89, G00--G02, G04--G07                                                                                                                                                                                                   040--046, 062--065, 320, 322--323
  Infections of the cardiovascular system                                                                                         I00--I02, I30.1, I32.0--I32.1, I33.0, I38, I39.8, I40.0, I41.0--I41.2, I43.0, I52.0--I52.1, I68.1, I98.1                                                                                                                       390-391, 420-424
  Infections of eyes and adnexa, the ear and mastoid process                                                                      H00, H01.0, H03.0--H03.1, H04.0, H04.3, H05.0, H06.1, H10, H13.1, H19.1--19.2, H22.0, H32.0, H44.0, H60.0--H60.3, H62.0--H62.4, H65.0, H66, H67.0--H67.1, H70, H73.0, H75.0, H94.0                                             361--362, 364, 366.00, 367.00, 368.00, 368.05, 369.00--369.01, 380--384
  Infections of respiratory tract                                                                                                 J00--J06, J09--J18, J20--J22, J34.0, J36, J39.0--J39.1, J44.0, J85--J86                                                                                                                                                        034, 460--466, 470--474, 480--486, 501, 503, 508.00--508.3, 508.5, 510, 513
  Infections of the digestive system                                                                                              A00--A09, B15--B19, K04.0, K04.6, K04.7, K05.2, K11.2--K11.3, K12.2, K23.0--K23.1, K35, K37, K57.0, K57.2, K57.4, K57.8, K61, K63.0, K65.0, K67, K75.0--K75.1, K77.0, K80.0, K80.3--K80.4, K81.0, K83.0, K85.9, K93.0--K93.1   000--009, 070, 522.59, 527.39, 528.39, 530--542, 567, 569, 572, 575, 577.03
  Infections of the skin, subcutaneous tissue, and musculoskeletal system                                                         A46, L00--L03, L05--L08, M00--M03, M46.3, M46.5, M49.0--M49.3, M60.0, M63.0--M63.2, M65.0--M65.1, M68.0, M71.0--M71.1, M86, M90.0--M90.2                                                                                       035, 522.59, 566.00, 680--686, 710--711, 720, 732.99
  Infections of the urinary tract, male and female genital system and sexually transmitted infections                             A50--A64, N10--N12, N15.1, N16.0, N29.1, N30.0, N33.0, N34.0--N34.1, N39.0, N41, N43.1, N45, N48.1--N48.2, N49, N51, N61, N70--77                                                                                              090--099, 590, 595, 599.00, 599.06, 597.03, 601, 604, 612--614, 616, 620, 622, 626.49
  SIRS, severe sepsis, and septic shock                                                                                           R57.2, R65.0--R65.1                                                                                                                                                                                                            038
  Other infectious diseases (other virus and parasitic infections, infections following transfusion, or chirurgical procedures)   A92--A99, B00--B09, B20--B89, B97, D73.3, E06.0, E06.9, E32.1, R75, T80.2, T81.4, T82.6--T82.7, T83.5--T83.6, T84.5--T84.7, T85.7, T88.0                                                                                       010--018, 020--033, 036--039, 050--057, 060--061, 067--068, 070--079, 080--089, 100--104, 110--117, 120--134, 997.69, 998.59, 998.79, 999.39
  Other bacterial infections                                                                                                      A15--A19, A20--A45, A47--A49, A65--A79, B95--B96, B98                                                                                                                                                                          010--018, 020--033, 036--039, 080--083, 088--089,100--104

###### 

Infections according to pathogens (ICD-10 codes and equivalence ICD-8 codes)

  Pathogen                 ICD-10 code                                                       ICD-8 code
  ------------------------ ----------------------------------------------------------------- ----------------------------------------------------------------------
  Bacteria                 A00--A05, A15--A56, A65--A79, B95--B96, B98                       000--005, 010--019, 020--039, 080--083, 088--089, 091--098, 100--104
  Virus                    A08, A60, A80--A89, A92--A99, B00--B09, B15--B19, B20--B34, B97   040--057, 060--065, 067--068, 070--079
  Varicella-zoster virus   B01--B02                                                          052--053
  Fungal or parasite       A06--A07, A59, B35--B89                                           006--007, 084--087, 110--117, 120--133

###### 

Community-based anti-infective prescription typically used for common community infections (ATC codes)

  Community infection                            Anti-infective treatment (ATC code)
  ---------------------------------------------- -------------------------------------
  Respiratory tract bacterial infections         Phenoxymethylpenicillin (J01CE02)
  Pivampicillin (J01CA02)                        
  Amoxicillin (J01CA04)                          
  Amoxicillin and enzyme inhibitor (J01CR02)     
  Erythromycin (J01FA01)                         
  Roxithromycin (J01FA06)                        
  Clarithromycin (J01FA09)                       
  Urinary tract bacterial infections             Pivmecillinam (J01CA08)
  Sulfamethizole (J01EB02)                       
  Trimethoprim (J01EA01)                         
  Sulfamethoxazole and Trimethoprim (J01EE01)    
  Nitrofurantoin (J01XE01)                       
  Skin or soft tissue bacterial infections       Dicloxacillin (J01CF01)
  Flucloxacillin (J01CF05)                       
  Tuberculosis                                   Antimycobacterials (J04A)
  Skin mycosis                                   Ketoconazole (J02AB02)
  Herpes simplex or varicella-zoster infection   Aciclovir (J05AB01)

###### 

List of all confounders in the study (ICD-10 codes and equivalence ICD-8 codes, or ATC codes)

  Confounder                                                              ICD-10 code                                                                                      ICD-8 code                                        ATC code
  ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------- -------------
  Chronic alcoholism-related disorders                                    E24.4, F10.1--F10.9, G31.2, G62.1, G72.1, I42.6, K29.2, K70, K85.2, K86.0, Z50.2, Z71.4, Z72.1   291, 303, 571.09, 571.10, 577.10, 860, 979, 980   
  Diabetes                                                                E10--E14, H28.0, H36.0, G59.0, G63.2, M14.2, N08.3                                               249, 250                                          
  Disorders involving the immune system                                   D70--D72, D73.0, D80--D84, D89                                                                   288, 289                                          
  Chronic kidney diseases[\*](#tfn10-clep-10-1533){ref-type="table-fn"}   I12.0, I13.1, I13.2, N02, N03, N05--N07, N08.3, N18, N19, N26, Z94.0                             403, 404, 582--584                                
  Malnutrition                                                            E40--E64                                                                                         260--269                                          
  Malignancies                                                            C00--C97                                                                                         140--208                                          
  Immunosuppressive treatments                                                                                                                                                                                               L01--L04
  Oral corticosteroid treatments                                                                                                                                                                                             H02AB, H02B

**Note:**

Defined from diagnosis of chronic glomerulonephritis, chronic tubule intestinal nephropathy, diabetic and hypertensive nephropathy, and renal sclerosis and chronic renal failure.

**Disclosure**

The authors report no conflicts of interest in this work.

###### 

Characteristics of GCA/PMR case and control populations from the Central and the North Denmark Region, 1997--2012

  Characteristic                         Cases (%)      Controls (%)
  -------------------------------------- -------------- ---------------
                                         (N=7,225)      (N=72,250)
  Gender                                                
   Female                                4,648 (64.3)   46,480 (64.3)
   Male                                  2,577 (35.7)   25,770 (35.7)
  Age (years)                                           
   Range                                 50--102        49--102
   Median (first, third quartile)        75 (67--81)    74 (67--81)
   Mean                                  74             74
  Comorbidities                                         
   Chronic alcoholism-related diseases   89 (1.2)       1,088 (1.5)
   Diabetes                              546 (7.6)      4,021 (5.6)
   Disorders of the immune system        18 (0.2)       201 (0.3)
   Chronic kidney diseases               129 (1.8)      828 (1.1)
   Malnutrition                          53 (0.7)       453 (0.6)
   Malignancies                          717 (9.9)      8,162 (11.3)
  Specific treatments                                   
   Immunosuppressive treatment           209 (2.9)      1,364 (1.9)
   Oral corticosteroid treatment         4,190 (58.0)   17,683 (24.5)

**Abbreviation:** GCA/PMR, giant cell arteritis and polymyalgia rheumatica.

###### 

Crude and adjusted OR for GCA/PMR case and control populations associated with hospital-treated infection and community-based anti-infective prescription, excluding events occurring 1 year prior the index date

  Exposure                                            Cases N (%)    Controls N (%)   Unadjusted OR (95% CI)   Adjusted OR[a](#tfn2-clep-10-1533){ref-type="table-fn"} (95% CI)
  --------------------------------------------------- -------------- ---------------- ------------------------ ------------------------------------------------------------------
  Hospital-treated infection                          2,426 (33.6)   20,806 (28.8)    1.26 (1.19--1.32)        1.04 (0.98--1.10)
  Infection according to the system involved                                                                   
   Nervous system                                     26 (0.4)       247 (0.3)        1.05 (0.70--1.58)        0.99 (0.65--1.51)
   Cardiovascular system                              42 (0.6)       292 (0.4)        1.44 (1.04--2.00)        1.23 (0.88--1.72)
   Eyes, ears, and mastoid process                    147 (2.0)      1,204 (1.7)      1.23 (1.03--1.46)        1.12 (0.93--1.34)
   Respiratory tract                                  760 (10.5)     6,435 (8.9)      1.20 (1.11--1.30)        0.91 (0.84--0.99)
   Digestive system                                   897 (12.4)     7,552 (10.5)     1.22 (1.13--1.31)        1.05 (0.98--1.14)
   Skin and musculoskeletal systems                   379 (5.2)      3,095 (4.3)      1.24 (1.11--1.38)        1.07 (0.96--1.20)
   Urinary tract and genital systems                  616 (8.5)      5,040 (7.0)      1.25 (1.14--1.36)        1.09 (1.00--1.20)
   Septic states                                      11 (0.2)       94 (0.1)         1.17 (0.63--2.19)        1.17 (0.61--2.24)
   Other infectious diseases                          15 (0.2)       141 (0.2)        1.07 (0.62--1.83)        1.14 (0.65--1.99)
   Other bacterial infections                         407 (5.6)      3,282 (4.5)      1.26 (1.13--1.40)        1.07 (0.95--1.19)
  Infection according to the pathogen                                                                          
   Bacteria                                           277 (3.8)      2,141 (3.0)      1.31 (1.15--1.49)        1.11 (0.97--1.27)
   Virus                                              143 (2.0)      1,113 (1.5)      1.29 (1.08--1.54)        1.13 (0.94--1.35)
   Varicella-zoster virus                             42 (0.6)       375 (0.5)        1.14 (0.82--1.59)        1.04 (0.74--1.46)
   Fungal or parasite                                 57 (0.8)       471 (0.7)        1.21 (0.92--1.60)        1.02 (0.77--1.36)
  All community-based anti-infective prescription     6,147 (85.1)   58,677 (81.2)    1.41 (1.31--1.52)        1.07 (0.99--1.16)
  Specific subgroups of anti-infective prescription                                                            
   Used for respiratory tract infection               5,044 (69.8)   46,994 (65.0)    1.30 (1.23--1.38)        0.99 (0.94--1.06)
   Used for urinary tract infection                   2,178 (30.1)   21,204 (29.3)    1.05 (0.99--1.11)        0.92 (0.86--0.97)
   Used for skin or soft tissue infection             874 (12.1)     8,151 (11.3)     1.09 (1.01--1.17)        0.91 (0.84--0.99)
   Used for tuberculosis                              10 (0.1)       55 (0.1)         1.82 (0.93--3.57)        1.31 (0.65--2.63)
   Used for skin mycosis                              18 (0.2)       133 (0.2)        1.36 (0.83--2.22)        1.06 (0.64--1.77)
   Used for herpes or varicella-zoster infection      366 (5.1)      2,751 (3.8)      1.36 (1.21--1.52)        1.20 (1.07--1.35)

**Notes:**

OR adjusted for diabetes, chronic alcoholism-related diseases, disorders involving the immune system, immunosuppressive treatment including corticosteroids, chronic kidney insufficiency, malnutrition, and neoplasia (see [Table S5](#SD5-clep-10-1533){ref-type="supplementary-material"} for ATC codes).

**Abbreviations:** GCA/PMR, giant cell arteritis and polymyalgia rheumatica; ATC, anatomical therapeutic chemical.

###### 

Crude and adjusted OR for GCA/PMR case and control populations associated with hospital-treated infection and community-based anti-infective prescription, including only events occurring 1 year prior the index date

  Exposure                                            Cases N (%)    Controls N (%)   Unadjusted OR (95% CI)   Adjusted OR[a](#tfn4-clep-10-1533){ref-type="table-fn"} (95% CI)
  --------------------------------------------------- -------------- ---------------- ------------------------ ------------------------------------------------------------------
  Hospital-treated infection                          582 (8.1)      3,074 (4.3)      1.99 (1.81--2.18)        1.59 (1.44--1.75)
  Infections according to the system involved                                                                  
   Nervous system                                     6 (0.1)        0 (0.0)          3.53 (1.39--8.96)        3.28 (1.24--8.88)
   Cardiovascular system                              5 (0.1)        19 (0.0)         2.63 (0.98--7.05)        2.51 (0.90--6.98)
   Eyes, ears, and mastoid process                    11 (0.2)       26 (0.1)         1.13 (0.54--1.96)        1.03 (0.54--1.96)
   Respiratory tract                                  78 (3.7)       97 (0.1)         1.99 (1.73--2.28)        2.10 (1.62--2.72)
   Digestive system                                   68 (0.9)       483 (0.7)        1.41 (1.10--1.82)        1.27 (0.98--1.66)
   Skin and musculoskeletal systems                   84 (1.2)       320 (0.4)        2.65 (2.08--3.37)        2.15 (1.67--2.78)
   Urinary tract and genital systems                  156 (2.2)      848 (1.2)        1.87 (1.57--2.22)        1.53 (1.28--2.22)
   Septic states                                      0 (0.0)        0 (0.0)          0.00 (0.00--0.00)        0.00 (0.00--0.00)
   Other infectious diseases                          0 (0.0)        0 (0.0)          0.00 (0.00--0.00)        0.00 (0.00--0.00)
   Other bacterial infections                         86 (1.2)       458 (0.6)        1.89 (1.50--2.38)        1.58 (1.24--2.01)
  Infection according to the pathogen                                                                          
   Bacteria                                           89 (1.2)       386 (0.5)        2.32 (1.84--2.93)        1.90 (1.49--2.42)
   Virus                                              19 (0.3)       131 (0.2)        1.45 (0.90--2.35)        1.18 (0.72--1.95)
   Varicella-zoster virus                             4 (0.1)        35 (0.0)         1.14 (0.41--3.22)        0.95 (0.33--2.75)
   Fungal or parasite                                 12 (0.2)       64 (0.1)         1.88 (1.01--3.49)        1.54 (0.81--2.95)
  All community-based anti-infective prescription     3,367 (46.6)   23,561 (32.6)    1.75 (1.67--1.84)        1.63 (1.48--1.79)
  Specific subgroups of anti-infective prescription                                                            
   Used for respiratory tract infection               2,486 (34.4)   15,738 (21.8)    1.90 (1.80--2.00)        1.53 (1.45--1.62)
   Used for urinary tract infection                   1,071 (14.8)   8,326 (11.5)     1.36 (1.26--1.46)        1.21 (1.12--1.30)
   Used for skin or soft tissue infection             272 (3.8)      2,183 (3.0)      1.26 (1.11--1.43)        1.03 (0.90--1.18)
   Used for tuberculosis                              1 (0.0)        13 (0.0)         0.77 (0.10--5.88)        0.62 (0.08--4.84)
   Used for skin mycosis                              4 (0.1)        16 (0.0)         2.50 (0.84--7.48)        2.10 (0.68--6.51)
   Used for herpes or varicella-zoster infection      65 (0.9)       540 (0.7)        1.21 (0.93--1.56)        1.05 (0.81--1.37)

**Notes:**

OR adjusted for diabetes, chronic alcoholism-related diseases, disorders involving the immune system, immunosuppressive treatment including corticosteroids, chronic kidney insufficiency, malnutrition, and neoplasia (see [Table S5](#SD5-clep-10-1533){ref-type="supplementary-material"} for ATC codes).

**Abbreviations:** GCA/PMR, giant cell arteritis and polymyalgia rheumatica; ATC, anatomical therapeutic chemical.

###### 

Crude and adjusted OR for PMR or GCA subgroups and control populations associated with hospital-treated infection and community-based anti-infective prescription

  Exposure                                                                                                              GCA subgroup (N=100)   PMR subgroup (N=5,100)   GCA+PMR subgroup (N=2,025)                                 
  --------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------ ---------------------------- -------------- -------------- ------
  Hospital-treated infection excluding 1 year prior to the index date                                                   1.33                   1.15                     1.23                         1.00           1.32           1.15
  (1.21--1.46)                                                                                                          (1.04--1.27)           (1.15--1.30)             (0.94--1.07)                 (1.20--1.46)   (1.04--1.27)   
  All community-based anti-infective prescription excluding 1 year prior to the index date                              1.33                   1.11                     1.45                         1.05           1.31           1.09
  (1.16--1.52)                                                                                                          (0.97--1.27)           (1.33--1.59)             (0.95--1.15)                 (1.14--1.50)   (0.95--1.25)   
  Hospital-treated infection including only events occurring in the year prior to the index date                        2.65                   2.36                     1.85                         1.41           2.35           2.07
  (1.24--5.67)                                                                                                          (1.04--5.33)           (1.66--2.07)             (1.25--1.59)                 (1.98--2.79)   (1.73--2.47)   
  All community-based anti-infective prescription including only events occurring in the year prior to the index date   2.21                   1.81                     1.70                         1.35           1.87           1.62
  (1.44--3.39)                                                                                                          (1.16--2.82)           (1.60--1.80)             (1.27--1.44)                 (1.70--2.05)   (1.47--1.78)   

**Notes:**

OR adjusted for diabetes, chronic alcoholism-related diseases, disorders involving the immune system, immunosuppressive treatment including corticosteroids, chronic kidney insufficiency, malnutrition, and neoplasia (see [Table S5](#SD5-clep-10-1533){ref-type="supplementary-material"} for ATC codes).

**Abbreviations:** GCA, giant cell arteritis; PMR, polymyalgia rheumatica; ATC, anatomical therapeutic chemicals.

###### 

Crude and adjusted OR for positive or negative temporal artery biopsy (TAB) subgroups and control populations associated with hospital-treated infection and community-based anti-infective prescription

  Exposure                                                                                                              GCA patient subgroup with negative TAB (N=1,615)   GCA patient subgroup with positive TAB (N=510)                  
  --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- ------------------------------------------------ -------------- ------
  Hospital-treated infection excluding 1 year prior to the index date                                                   1.50                                               1.26                                             0.86           0.81
  (1.35--1.67)                                                                                                          (1.13--1.41)                                       (0.70--1.07)                                     (0.65--1.01)   
  All community-based anti-infective prescription excluding 1 year prior to the index date                              1.53                                               1.26                                             0.88           0.78
  (1.30--1.79)                                                                                                          (1.07--1.49)                                       (0.68--1.14)                                     (0.60--1.02)   
  Hospital-treated infection including only events occurring in the year prior to the index date                        2.63                                               2.26                                             1.56           1.57
  (2.18--3.17)                                                                                                          (1.86--2.75)                                       (1.06--2.31)                                     (1.05--2.35)   
  All community-based anti-infective prescription including only events occurring in the year prior to the index date   1.94                                               1.63                                             1.72           1.62
  (1.75--2.15)                                                                                                          (1.46--1.82)                                       (1.43--2.08)                                     (1.34--1.96)   

**Notes:**

OR adjusted for diabetes, chronic alcoholism-related diseases, disorders involving the immune system, immunosuppressive treatment including corticosteroids, chronic kidney insufficiency, malnutrition, and neoplasia (see [Table S5](#SD5-clep-10-1533){ref-type="supplementary-material"} for ATC codes).

**Abbreviations:** GCA, giant cell arteritis; ATC, anatomical therapeutic chemical; AB, temporal artery biopsy.
